Lack of Transient Receptor Potential

Introduction
Transient receptor potential vanilloid-1 (TRPV1) is a member of a family of TRPV receptors, which mediates stimuli of the sensory neuron and percepts heat by the nervous system. TRPV1 is known to be specifically activated not only by high temperatures (43 ° C) but also by various stimuli such as capsaicin. In addition to certain sensory neurons, TRPV1 has recently been reported to be expressed (albeit at much lower levels compared with sensory neurons) in various nonneuronal cells, such as keratinocytes [1] , smooth muscle cells [2] , endothelial cells [3] and cells of the immune system, including mast cells, lymphocytes and dendritic cells (DCs) [4] [5] [6] [7] .
In the airways, TRPV1 has been proposed to play a role in several features of respiratory diseases, including
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TRPV1 may also contribute to the development of airway inflammation seen in asthma. Several evidences have been demonstrated to support this hypothesis. First, interactions between neuropeptides such as tachykinins and inflammatory cells such as macrophages and mast cells are reported [11] . These cells are known to modulate immune responses. Second, heat, one of the major causative stimuli of TRPV1 receptor, has an equally profound effect on the immune system [12] [13] [14] [15] , although its perception by the immune system is poorly understood. Third, as mentioned above, TRPV1 is shown to be expressed on cells of the immune system, including mast cells, lymphocytes and DCs [4] [5] [6] [7] , all of which are important in the development of adoptive immunity.
Thus, in the present study, we wanted to know the role of TRPV1 in the development of allergic airway sensitization. For this purpose, we examined the characteristics of the response in TRPV1 receptor gene knockout mice (TRPV1 -/-) after sensitization and challenge with allergens. TRPV1
-/-and wild-type C57BL/6 mice (TRPV1 +/+ ) were sensitized with two different allergens via different routes: intranasal (i.n.) and intraperitoneal (i.p.). Then, the animals were intranasally challenged with the corresponding allergen. As the allergens, we used ovalbumin (OVA) and house dust mite (HDM), major food and inhalant allergens in allergic individuals, respectively.
Animals and Methods
Animals
Wild-type mice (C57BL/6) purchased from Japan SLC (Shizuoka, Japan) and TRPV1-deficient mice [16] backcrossed on a C57BL/6 background were used. The TRPV1 -/-mice were provided by Dr. D. Julius [16] and were reared in the animal care facilities of Takasaki University of Health and Welfare. All experiments were performed using 7-to 9-week-old male animals. All mice were bred under specific pathogen-free conditions at 24-25 ° C and a 12-hour/12-hour light/dark cycle provided with standard chow and water ad libitum. All procedures were conducted in accordance with the policy of the Animal Care and Use Committee at the Takasaki University of Health and Welfare.
Sensitization and Airway Challenge Protocol
Eight experimental groups with corresponding nonsensitized controls were developed (7-11 and 5-8 mice for each sensitized and nonsensitized group, respectively). TRPV1 -/-and their wild-type counterparts (TRPV1 +/+ ) were sensitized with either HDM (Mite extract-Df; Cosmo Bio, Tokyo, Japan) or OVA (grade V; Sigma-Aldrich, St. Louis, Mo., USA) via i.n. or i.p. route before the final i.n. challenge with the corresponding antigen. The nonsensitized animal in each group was given same volume of vehicle instead of each allergen. The allergen exposure protocols were as follows: animals given i.n. HDM sensitization: HDM was given by modifying the protocol by Shibamori et al. [17] . Mice were anesthetized with an i.p. injection of 50 mg/kg of sodium pentobarbital, followed by i.n. instillation of 100 g of HDM in 50 l of PBS or the same volume of PBS. The same dose of allergen or PBS alone was given intranasally on 5 consecutive days (days 0-4) and days 14 as well as 15, and challenged on days 21 and 22.
Animals given i.p. HDM sensitization: mice were immunized intraperitoneally with 10 g of HDM in 1 mg of alum (AlOH 3 ) or 1 mg of alum alone on day 0 and boosted on days 7 and 14. Subsequently, mice were anesthetized with sodium pentobarbital and 100 g of HDM in 50 l PBS or PBS alone, and were challenged via i.n. instillation on days 21 and 22.
Animals given i.n. OVA sensitization: using 100 g of OVA instead of HDM, allergen sensitization and challenge were carried out with the same schedule as the protocol of i.n. HDM sensitization.
Animals given i.p. OVA sensitization: mice were immunized intraperitoneally with 10 g of OVA in 1 mg of AlOH 3 or alum alone on day 0 and boosted on days 7 and 14 as described previously [18] . After anesthesia, 2 mg of i.n. OVA in 50 l PBS or PBS alone were given twice on day 21 and once on days 22 and 23.
Determination of Bronchial Hyperresponsiveness
Twenty-four hours after the last allergen challenge, mice were anesthetized with 50 mg/kg pentobarbital and instrumented for the measurement of pulmonary mechanics (BUXCO Electronics, Suita, Japan). Mice were tracheostomized, intubated and mechanically ventilated at a tidal volume of 0.2 ml and a frequency of 150 breaths/min. Mice were paralyzed with suxamethonium chloride (5 mg/kg i.p.). Baseline lung resistance (R L ) and responses to aerosolized saline (0.9% NaCl) were measured first, followed by responses to increasing doses (0.19 to 500 mg/ml) of aerosolized acetyl-methylcholine chloride (methacholine, Mch; SigmaAldrich). The highest values of R L were obtained after each dose of Mch. Bronchial hyperresponsiveness (BHR) was evaluated utilizing 3 parameters: (1) Mch concentration required for 100% R L increase from the baseline value referred to as PC 200 , (2) the leftward shift of the dose-response curve, (3) the absolute value of R L corresponding to the maximum Mch concentration (500 mg/ml) referred to as maximum reactivity (MaxR).
The Sampling Procedure of Blood and Bronchoalveolar Lavage Fluid
After assessment of BHR, mice were sacrificed and blood was collected by cardiac puncture to obtain serum samples. After getting the samples, lungs were lavaged with 0.4 ml of phosphate-buffered saline (pH 7.4) 3 times. The bronchoalveolar lavage fluids (BALF) were centrifuged at 3,000 rpm for 5 min. The supernatant was preserved for the measurement of cytokine levels at -70 ° C. The cell pellet was resuspended in 0.3 ml of phosphate-buffered saline. The total cell counts were performed with a hemocytometer, and the differential cell counts were performed on cytospin preparations stained with Diff-Quick (Kokusai-Siyaku, Tokyo, Japan). A blinded observer counted a minimum of 200 cells for each sample.
Determination of Total IgE Antibodies
Total IgE levels were measured by using commercially available ELISA kits (Shibayagi, Shibukawa, Japan).
Measurement of BALF Cytokines
IL-4, IFN-␥ , IL-5 and eotaxin levels were measured by commercially available ELISA kits (for IL-4 and IFN-␥ : Endogen, Boston, Mass., USA; for IL-5 and eotaxin: R&D Systems, Minneapolis, Minn., USA). The detection limit was 15 pg/ml for all these cytokines.
Statistical Analysis
All data are expressed as means 8 SEM, unless mentioned otherwise. Nonparametric analysis of variance (Kruskal-Wallis test for unmatched pairs) was used to determine the significance of variance between groups. If a significance of variance was found, a Mann-Whitney U test was performed to assess the significance of differences between groups. A p value of less than 0.05 was considered to indicate statistical significance. The statistical analysis was performed utilizing Statview version 4.5 (Avacus Concepts Inc., Berkeley, Calif., USA).
Results
Total IgE Levels
In all groups of TRPV1 +/+ given sensitization and challenge with allergen, total IgE level did not differ from corresponding animals without sensitization. In TRPV1 -/-, a significant increase in total IgE level was found in animals sensitized and challenged with HDM compared to nonsensitized animals, irrespective of the route of sensitization. In TRPV1 -/-given i.n. sensitization with HDM, total IgE level was significantly higher than that in corresponding TRPV1 +/+ , although this was not the case in those given i.p. sensitization ( fig. 1 a, b) . In TRPV1 -/-given i.n. sensitization with OVA, IgE level was significantly higher than that in corresponding TRPV1 +/+ , although no difference was found between TRPV1 -/-with and without i.n. OVA sensitization. In TRPV1 -/-given i.p. sensitization, no increase in IgE levels was found ( fig. 1 c, d ).
BALF Cytokine Levels
In TRPV1 +/+ , significant increase in BALF IL-4 was observed in those given sensitization with HDM, irrespective of the route. By contrast, no significant increase was found in those sensitized with OVA. In TRPV1 
Cells in the BALF
Total cells in the BALF increased in all groups of animals given sensitization and challenge compared to corresponding animals given vehicle. In animals given sensitization with i.n. OVA, the number of total cells in TRPV1 -/-was significantly higher than that in TRPV1 +/+ . In detail, the numbers of eosinophils, neutrophils, macrophages and lymphocytes were significantly increased ( fig. 5a-d) 
Discussion
We have examined the remarks of allergic airway and systemic responses in TRPV1 receptor gene knockout mice. As a result, TRPV1
-/-showed an enhanced Th2-biased response against i.n. HDM or OVA exposure, including increased levels of serum IgE, and IL-4 and eosinophils in the BALF. By contrast, when sensitized via i.p. route, the difference was not obvious between TRPV1 +/+ and TRPV1 -/-. These results suggest that TRPV1 receptor may downregulate Th2-biased immune response when sensitized via airways, although this was not the case when sensitized systemically.
In the present study, we used C57BL/6 strain as TRPV1 +/+ and TRPV1 -/-. We chose the strain because the knockout mice we had been provided were limited only to that one. In TRPV1 +/+ , sensitization and challenge with allergens did not induce remarkable Th2-biased immune response, that is, total IgE in the serum did not elevate in any of the groups with sensitization, and IL-4 as well as IL-5 levels were not significantly increased in OVA-treated animals irrespective of the route of sensitization, although eosinophil counts in the BALF increased in all groups given sensitization with allergens. These results confirmed previous observations that the C57BL/6 strain was one of those with less responsiveness to allergen exposure [17, 19, 20] . Shinagawa et al. [20] showed that, in repeated OVA instillation into the nose, eosinophilic inflammation, airway wall thickening and BHR were not observed in C57BL/6 and C3H/HeJ mice, whereas obvious responses were found in A/J and BALB/c mice. As for i.n. HDM exposure, Shibamori et al. [17] demonstrated that NC/Nga mice showed the strongest response, including the number of eosinophils in the BALF, BHR, Th2 cytokine (IL-5 and IL-13) and chemokine (eotaxin-1 and eotaxin-2) levels in the BALF, compared to C57BL/6N, A/J, BALB/c and CBA/JN strains. It was interesting that local Th2 cytokines and the number of eosinophils, in addition to serum IgE levels, increased in TRPV1 -/-compared to TRPV1 +/+ . These results suggest that TRPV1 receptor attenuates Th2-biased immune response, indicating that this receptor has an inhibitory effect against the development of allergic airway inflammation. Several possibilities may arise, although we could not clarify the underlying mechanism. First, it is possible that TRPV1 receptors located in nerve endings downregulate Th2-biased responses by releasing sensory neuropeptides such as substance P, neurokinin A, calcitonin gene-related peptide and, possibly, soma- tostatin [21] . Topically applied allergens have been shown to react with the sensitized local mast cells and then these cells release several inflammatory mediators such as histamine and leukotrienes [22] . These mediators are known to activate TRPV1 which has been demonstrated to control the release of sensory neuropeptides [23] . Evidence has shown that the lack of TRPV1 decreases these peptides [24] , although we did not examine the expression patterns of sensory neuropeptides in TRPV1 -/-of the present study. It is recognized that the immune and nervous systems are closely integrated to optimize defense systems within the lung. When released, these neuropeptides are speculated to have effects on the activation of immune cells including T cells and professional antigenpresenting DCs [25] . Second, TRPV1 receptors expressed on immune cells may play a role. Recently, TRPV1 has been shown to be expressed not only on sensory nerve endings but also on cells of the immune system, including mast cells, lymphocytes and DCs [4] [5] [6] [7] , all of which have important roles in the development of adoptive immunity. Among these cells, conflicting findings are reported for the role of TRPV1 receptors in the function of DCs, a key cell type of the vertebrate immune system. Basu and Srivastava [26] demonstrated an expression of TRPV1 on DCs. They reported that engagement of TRPV1 on immature DCs such as by treatment with capsaicin leads to maturation of DCs as measured by upregulation of antigen-presenting and costimulatory molecules. Conversely, Toth et al. [27] demonstrated that capsaicin dose-dependently inhibited cytokine-induced DC differentiation, phagocytosis of bacteria, activation of DCs and proinflammatory cytokine secretion, indicating that TRPV1 receptors have an anti-inflammatory action on DCs. Our present findings may support the functional role of TRPV1 suggested by Toth et al. [27] . Further studies would be required concerning the mechanism of the results obtained in the present study.
Our present results showed that i.n., but not i.p., sensitization induced significant increases in the Th2 response in TRPV1 -/-. Our findings partly confirmed previous observations by Caceres et al. [28] demonstrating that airway and systemic responses caused by i.p. OVA sensitization did not differ between TRPV1 +/+ and TRPV1 -/-. Although they did not examine the effect of local application of allergens on airway response, they showed that genetic ablation of TRPA1, but not TRPV1 -/-, inhibited i.p. OVA-induced leukocyte infiltration in the airways, reduced cytokine and mucus production, and almost completely abolished airway hyperresponsiveness to contractile stimuli. Our present results suggested that the route of sensitization would be an important factor to evaluate airway effects. It was suggested that the airway sensitization via mucosal allergen entry might be required to activate TRPV1 receptors. In intraperitoneally sensitized animals, only 30 g of allergen in total was applied to peritoneum, reaching the airways mainly via blood flow. By contrast, 500 g of allergen in total was directly applied to the airway mucosa in animals sensitized intranasally.
In the present study, BHR was not induced in all groups of animals given sensitization compared to those given vehicle, irrespective of the route of sensitization. Conflicting results have been reported as for the BHR after OVA exposure in C57BL/6 mice. When given i.p. sensitization, several investigators found that there was no difference in BHR between animals with and without sensitization [19, [29] [30] [31] , while others indicated an increased bronchial responsiveness in animals given OVA compared to vehicle [28, 32, 33] . As for animals sensitized with i.n. OVA, no difference in the bronchial responsiveness between those with and without allergen exposure was demonstrated by several investigators [17, 20] . As for i.n. HDM exposure, Shibamori et al. [17] demonstrated that i.n. HDM exposure induced a weak but significant increase in bronchial responsiveness to Mch in C57BL/6N mice. We do not know the reason for the difference between their results and ours. The difference in the details of sensitization and challenge protocol or that in Mch provocation procedures might be the reasons. They gave Mch via intravenous route, while we did it by aerosol. They estimated BHR by the percentage of the respiratory overflow volume provoked by acetylcholine to the maximal overflow volume (100%) obtained by totally occluding the tracheal cannula, while we did it by measuring lung resistance.
Our results suggest that TRPV1 receptor has a protective role against Th2-biased immune response and, consequently, the development of allergic inflammation in the airways. This may shed light on the pharmacotherapy of allergic airway diseases such as asthma by using agonists of TRPV1 receptors, although further studies would be required.
